These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 39214049

  • 1. A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17).
    Kang EJ, Yang Y, Lee S, Kim YJ, Lim SM, Ahn MJ, Choi YJ, Lee Y, Kim TM, Kim I, Ahn HK, Jeung HC, Lee SI, Oh SY, Bae WK, Ryu H, Park KH, Lee KH.
    ESMO Open; 2024 Sep; 9(9):103668. PubMed ID: 39214049
    [Abstract] [Full Text] [Related]

  • 2. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
    Sakai H, Morise M, Kato T, Matsumoto S, Sakamoto T, Kumagai T, Tokito T, Atagi S, Kozuki T, Tanaka H, Chikamori K, Shinagawa N, Takeoka H, Bruns R, Straub J, Schumacher KM, Paik PK.
    Jpn J Clin Oncol; 2021 Aug 01; 51(8):1261-1268. PubMed ID: 34037224
    [Abstract] [Full Text] [Related]

  • 3. Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
    Morise M, Kato T, Matsumoto S, Inoue T, Sakamoto T, Tokito T, Atagi S, Kozuki T, Takeoka H, Chikamori K, Shinagawa N, Tanaka H, Horii E, Adrian S, Bruns R, Johne A, Paik PK, Sakai H.
    Cancer Sci; 2024 Apr 01; 115(4):1296-1305. PubMed ID: 38402853
    [Abstract] [Full Text] [Related]

  • 4. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
    Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, Chen YM, Chian CF, Liu X, Tan DSW, Bruns R, Straub J, Johne A, Scheele J, Park K, Yang JC, INSIGHT Investigators.
    Lancet Respir Med; 2020 Nov 01; 8(11):1132-1143. PubMed ID: 32479794
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
    Kato T, Yang JC, Ahn MJ, Sakai H, Morise M, Chen YM, Han JY, Yang JJ, Zhao J, Hsia TC, Berghoff K, Bruns R, Vioix H, Lang S, Johne A, Le X, Paik PK.
    Br J Cancer; 2024 Jun 01; 130(10):1679-1686. PubMed ID: 38575731
    [Abstract] [Full Text] [Related]

  • 6. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
    Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X.
    N Engl J Med; 2020 Sep 03; 383(10):931-943. PubMed ID: 32469185
    [Abstract] [Full Text] [Related]

  • 7. MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.
    Reale ML, Passiglia F, Cappuzzo F, Minuti G, Occhipinti M, Bulotta A, Delmonte A, Sini C, Galetta D, Roca E, Pelizzari G, Cortinovis D, Gariazzo E, Pilotto S, Citarella F, Bria E, Muscolino P, Pozzessere D, Carta A, Pignataro D, Calvetti L, Leone F, Banini M, Di Micco C, Baldini E, Favaretto A, Malapelle U, Novello S, Pasello G, Tiseo M.
    ESMO Open; 2024 Sep 03; 9(9):103680. PubMed ID: 39214048
    [Abstract] [Full Text] [Related]

  • 8. Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
    Mazieres J, Paik PK, Garassino MC, Le X, Sakai H, Veillon R, Smit EF, Cortot AB, Raskin J, Viteri S, Wu YL, Yang JCH, Ahn MJ, Ma R, Zhao J, O'Brate A, Berghoff K, Bruns R, Otto G, Johne A, Felip E, Thomas M.
    JAMA Oncol; 2023 Sep 01; 9(9):1260-1266. PubMed ID: 37270698
    [Abstract] [Full Text] [Related]

  • 9. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
    Tseng LW, Chang JW, Wu CE.
    Int J Mol Sci; 2022 Oct 05; 23(19):. PubMed ID: 36233109
    [Abstract] [Full Text] [Related]

  • 10. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
    Mathieu LN, Larkins E, Akinboro O, Roy P, Amatya AK, Fiero MH, Mishra-Kalyani PS, Helms WS, Myers CE, Skinner AM, Aungst S, Jin R, Zhao H, Xia H, Zirkelbach JF, Bi Y, Li Y, Liu J, Grimstein M, Zhang X, Woods S, Reece K, Abukhdeir AM, Ghosh S, Philip R, Tang S, Goldberg KB, Pazdur R, Beaver JA, Singh H.
    Clin Cancer Res; 2022 Jan 15; 28(2):249-254. PubMed ID: 34344795
    [Abstract] [Full Text] [Related]

  • 11. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
    Choi W, Park SY, Lee Y, Lim KY, Park M, Lee GK, Han JY.
    Cancer Res Treat; 2021 Oct 15; 53(4):1024-1032. PubMed ID: 33540494
    [Abstract] [Full Text] [Related]

  • 12. Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.
    Xiong W, Hietala SF, Nyberg J, Papasouliotis O, Johne A, Berghoff K, Goteti K, Dong J, Girard P, Venkatakrishnan K, Strotmann R.
    Cancer Chemother Pharmacol; 2022 Jul 15; 90(1):53-69. PubMed ID: 35771259
    [Abstract] [Full Text] [Related]

  • 13. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
    Fujino T, Suda K, Koga T, Hamada A, Ohara S, Chiba M, Shimoji M, Takemoto T, Soh J, Mitsudomi T.
    J Hematol Oncol; 2022 Jun 11; 15(1):79. PubMed ID: 35690785
    [Abstract] [Full Text] [Related]

  • 14. Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation.
    Takamori S, Matsubara T, Fujishita T, Ito K, Toyozawa R, Seto T, Yamaguchi M, Okamoto T.
    Thorac Cancer; 2021 Mar 11; 12(6):978-980. PubMed ID: 33533182
    [Abstract] [Full Text] [Related]

  • 15. Spatial profiling of METex14-altered NSCLC under tepotinib treatment: Shifting the immunosuppressive landscape.
    Simard MA, Cabrera-Galvez C, Viteri S, Geist F, Reischmann N, Zühlsdorf M, Karachaliou N.
    Neoplasia; 2024 Nov 11; 57():101063. PubMed ID: 39366215
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
    Drusbosky LM, Dawar R, Rodriguez E, Ikpeazu CV.
    J Hematol Oncol; 2021 Aug 23; 14(1):129. PubMed ID: 34425853
    [Abstract] [Full Text] [Related]

  • 17. Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations.
    Paik PK, Pfeiffer BM, Vioix H, Garcia A, Postma MJ.
    Adv Ther; 2022 Jul 23; 39(7):3159-3179. PubMed ID: 35543963
    [Abstract] [Full Text] [Related]

  • 18. Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer.
    Xia Y, Jin R, Li M, Lan F, Zhu H, Yu Y, Miao D, Wang Q, Zhou Y, Selvaggi G, Ying S, Zhang J, Shen H, Le X, Li W.
    Cancer Lett; 2023 May 01; 561():216140. PubMed ID: 36948240
    [Abstract] [Full Text] [Related]

  • 19. Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.
    Nosaki K, Yoh K, Toyozawa R, Horinouchi H, Morise M, Ohashi K, Murakami H, Satouchi M, Sakakibara-Konishi J, Yano S, Okumura F, Matsumoto S, Shimokawa M, Seto T, Goto K.
    Int J Clin Oncol; 2024 Aug 01; 29(8):1142-1151. PubMed ID: 38758397
    [Abstract] [Full Text] [Related]

  • 20. Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK.
    Batteson R, Hook E, Wheat H, Hatswell AJ, Vioix H, McLean T, Alexopoulos ST, Baijal S, Paik PK.
    Target Oncol; 2024 Mar 01; 19(2):191-201. PubMed ID: 38492157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.